These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1130 related items for PubMed ID: 23974954

  • 21. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
    Stoppino LP, Della Valle N, Rizzi S, Cleopazzo E, Centola A, Iamele D, Bristogiannis C, Stoppino G, Vinci R, Macarini L.
    BMC Med Imaging; 2016 May 05; 16(1):37. PubMed ID: 27149857
    [Abstract] [Full Text] [Related]

  • 22. A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy.
    Hall B, Holleran G, Chin JL, Smith S, Ryan B, Mahmud N, McNamara D.
    J Crohns Colitis; 2014 Dec 05; 8(12):1601-9. PubMed ID: 25257546
    [Abstract] [Full Text] [Related]

  • 23. Factors associated with short- and long-term outcomes of therapy for Crohn's disease.
    Reinisch W, Colombel JF, Sandborn WJ, Mantzaris GJ, Kornbluth A, Adedokun OJ, Miller M, Tang KL, Rutgeerts P, Cornillie F.
    Clin Gastroenterol Hepatol; 2015 Mar 05; 13(3):539-547.e2. PubMed ID: 25245629
    [Abstract] [Full Text] [Related]

  • 24. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G.
    Gastroenterology; 2012 May 05; 142(5):1102-1111.e2. PubMed ID: 22326435
    [Abstract] [Full Text] [Related]

  • 25. Association of clinical and inflammatory markers with small bowel capsule endoscopy findings in Crohn's disease.
    Mitselos IV, Katsanos KH, Tatsioni A, Skamnelos A, Eliakim R, Tsianos EV, Christodoulou DK.
    Eur J Gastroenterol Hepatol; 2018 Aug 05; 30(8):861-867. PubMed ID: 29697457
    [Abstract] [Full Text] [Related]

  • 26. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.
    Forbes GM, Sturm MJ, Leong RW, Sparrow MP, Segarajasingam D, Cummins AG, Phillips M, Herrmann RP.
    Clin Gastroenterol Hepatol; 2014 Jan 05; 12(1):64-71. PubMed ID: 23872668
    [Abstract] [Full Text] [Related]

  • 27. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M.
    Scand J Gastroenterol; 2013 May 05; 48(5):543-51. PubMed ID: 23477356
    [Abstract] [Full Text] [Related]

  • 28. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
    Turner D, Griffiths AM, Veerman G, Johanns J, Damaraju L, Blank M, Hyams J.
    Clin Gastroenterol Hepatol; 2013 Nov 05; 11(11):1460-5. PubMed ID: 23672831
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM, Liu T, Gao S, Tong XD, Deng FH, Nie B.
    World J Gastroenterol; 2017 Dec 14; 23(46):8235-8247. PubMed ID: 29290660
    [Abstract] [Full Text] [Related]

  • 30. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R.
    J Crohns Colitis; 2013 Dec 14; 7(12):958-67. PubMed ID: 23517933
    [Abstract] [Full Text] [Related]

  • 31. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
    Sandborn WJ, Colombel JF, D'Haens G, Plevy SE, Panés J, Robinson AM, Pollack PF, Zhou Q, Castillo M, Thakkar RB.
    Curr Med Res Opin; 2013 May 14; 29(5):483-93. PubMed ID: 23438483
    [Abstract] [Full Text] [Related]

  • 32. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
    Löwenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, Hindryckx P, Rispens T, de Vries A, van der Woude CJ, Berends S, Ambarus CA, Mathot R, Clasquin E, Baert F, D'Haens G.
    Gastroenterology; 2019 Oct 14; 157(4):997-1006.e6. PubMed ID: 31175865
    [Abstract] [Full Text] [Related]

  • 33. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho KL, Färkkilä M.
    J Crohns Colitis; 2013 Oct 14; 7(9):730-5. PubMed ID: 23182163
    [Abstract] [Full Text] [Related]

  • 34. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, Seidel L, Colombel JF, Louis E, GETAID (Groupe d'Étude Thérapeutique Des Affections Inflammatoires Digestives).
    J Crohns Colitis; 2013 Dec 14; 7(12):e678-83. PubMed ID: 23845231
    [Abstract] [Full Text] [Related]

  • 35. Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
    Rivière P, D'Haens G, Peyrin-Biroulet L, Baert F, Lambrecht G, Pariente B, Bossuyt P, Buisson A, Oldenburg B, Vermeire S, Laharie D.
    Am J Gastroenterol; 2021 Jan 01; 116(1):134-141. PubMed ID: 33177349
    [Abstract] [Full Text] [Related]

  • 36. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
    Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S.
    Clin Gastroenterol Hepatol; 2014 Jan 01; 12(1):80-84.e2. PubMed ID: 23891927
    [Abstract] [Full Text] [Related]

  • 37. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
    Jones J, Loftus EV, Panaccione R, Chen LS, Peterson S, McConnell J, Baudhuin L, Hanson K, Feagan BG, Harmsen SW, Zinsmeister AR, Helou E, Sandborn WJ.
    Clin Gastroenterol Hepatol; 2008 Nov 01; 6(11):1218-24. PubMed ID: 18799360
    [Abstract] [Full Text] [Related]

  • 38. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy.
    Lönnkvist MH, Theodorsson E, Holst M, Ljung T, Hellström PM.
    Scand J Gastroenterol; 2011 Apr 01; 46(4):420-7. PubMed ID: 21114432
    [Abstract] [Full Text] [Related]

  • 39. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease.
    Van Assche G, Herrmann KA, Louis E, Everett SM, Colombel JF, Rahier JF, Vanbeckevoort D, Meunier P, Tolan D, Ernst O, Rutgeerts P, Vermeire S, Aerden I, Oortwijn A, Ochsenkühn T.
    J Crohns Colitis; 2013 Dec 01; 7(12):950-7. PubMed ID: 23411006
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of azathioprine in mild or moderate relapse in Crohn's disease: clinical and endoscopic evaluation.
    Murakami Y, Matsui T, Hirai F, Takatsu N, Takaki Y, Nagahama T, Hisabe T, Beppu T, Miyaoka M, Maki S, Takeichi M, Nishimura T, Ueki T, Yao K.
    Dig Endosc; 2010 Jan 01; 22(1):25-32. PubMed ID: 20078661
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.